Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...
Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...
CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.
Lung cancer varies widely from patient to patient, and that diversity makes it hard to find effective treatments. Researchers ...
Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.
CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...
Oscar Murphy has an aggressive form of the blood cancer and is the first to get CAR-T therapy in the UK.
Strategies for using measurable residual disease to guide treatment decisions around the time of transplant in acute leukemia, featured in an education session and Hematology publication. Real-world ...
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...
Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...
Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...
Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results